In The News Posted December 8, 2019 Share Posted December 8, 2019 STOCKHOLM, Dec. 8, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented results from an online survey highlighting disease burden and impact for patients with immune thrombocytopenia (ITP), at the 61st Annual Meeting... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.